ABSTRACT
SARS-CoV-2 nucleocapsid antigen (N-Ag) can be detected in the blood of patients with Covid-19. In this study, we used a highly sensitive and specific nucleocapsid-Ag assay to explore the presence of N-Ag in urine during the course of Covid-19, and explore its relationship with the severity of the disease in 82 hospitalized patients.
High urinary N-Ag levels were associated with, admission in intensive care units, high C-reactive protein levels, lymphopenia, eosinopenia, high lactate dehydrogenase (LDH), and absence of SARS-CoV-2 nucleocapsid-IgG.
Our study demonstrate that N-Ag is present in the urine of patients hospitalized in the early phase of Covid-19. As a direct marker of SARS-CoV-2, urinary N-Ag reflects the dissemination of viral compounds in the body. Urine N-Ag is a promising marker to predict adverse evolution of SARS-CoV-2 infections.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04347850
Funding Statement
This work was funded by the Montpellier University Hospital, Muse I‐SITE Program Grant, University of Montpellier.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The cohort study received an institutional ethics committee approval (CPP Ile de France III, number 2020‐A00935−34; ClinicalTrials. gov Identifier: NCT04347850).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets analysed during the current study are available from the corresponding author on reasonable request.